Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-10-28 (biospace.com)
Evolving FDA Accelerated Approval Pathway Suffers Spate of Withdrawals
As therapies for rare and neurological diseases earn accelerated approval, experts laud the program’s intent while remaining concerned about confirmatory trials and clinical efficacy, especially as products greenlit under this pathway are pulled from the market.
Read more
2024-10-11 (csimarket.com)
Evolving SMA Therapy Promising Data on Higher-Dose Nusinersen from the DEVOTE Study Presented at WMS 2024,
*Exploring New Frontiers in Spinal Muscular Atrophy Management: Insights from the DEVOTE Study on Higher-Dose Nusinersen*Recent advancements in the treatment of spinal muscular atrophy (SMA) are shifting paradigms and offering new hope for patients and their families. At the forefront of this
Read more
2024-10-01 (technologynetworks.com)
The Evolving Treatment Landscape for Alzheimer’s
Explore the latest advances in Alzheimer's treatments, from novel drug therapies to emerging research, reshaping the future of care for patients.
Read more
2024-09-25 (elpais.com)
A scientific rebellion to get Europe to approve a controversial Alzheimer’s drug
The new monoclonal antibody lecanemab has been greenlighted by the US and other countries, but the European Medicines Agency considers that the benefits do not outweigh the risks
Read more
2024-07-13 (theretirementgroup.com)
Financial Benefits for Biogen Employees Aged 65 and Above
Discover financial benefits for Biogen employees aged 65+. Optimize your retirement strategy with our expert insights tailored for Biogen retirees.
Read more
2024-03-04 (biospace.com)
New ALS Treatments Face Regulatory Uncertainty | BioSpace
Despite the approval of two novel therapies for this uniformly fatal neurodegenerative disease, experts say regulatory standards and expectations are still evolving.
Read more
2024-02-13 (boerse-express.com)
Less multiple sclerosis business: Biogen sales fall - Alzheimer's in focus
CAMBRIDGE (dpa-AFX) - Weaker business with drugs against multiple sclerosis put pressure on Biogen's sales in 2023. Sales of drugs against nervous diseases fell by 14 percent to around 4.7 billion US dollars compared to the previous year, according to the US pharmaceutical company
Read more
2024-02-09 (pharmaceuticaldaily.com)
Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions
New partnership model leverages Aptar Digital Health’s capabilities to support the development and operation of new and existing digital health solutions globally Initial scope of multi-year agreem...
Read more
2024-01-12 (pharmaceutical-technology.com)
FDA yet to find link between suicidal risk and GLP-1RA use
The leading site for news and procurement in the pharmaceutical industry
Read more
2023-11-29 (pharmiweb.com)
Pulmonary Fibrosis Biomarkers Market Anticipates a Remarkable Valuation of US$ 6.2 Billion by 2033-F
The global Pulmonary Fibrosis Biomarkers Market is on a trajectory of substantial growth, with a projected market size of US$ 4.1 billion in 2023 and an anticipated CAGR of 4.2% during the forecast period, propelling it to a valuation of US$ 6.2 billion by 2033.Key to this growth is the rapid adv...
Read more
2023-11-14 (finmarket.ru)
Investbank
Investment bank ``Sinara'' maintains ``hold'' rating for Tesla shares with outlook
Read more
2023-11-14 (bisnow.com)
Norges Bank Buys Stake In Kendall Square Lab Developments At $1.7B Valuation
The Norwegian sovereign wealth fund manager bought a 45% stake in two Boston Properties life sciences projects for $746.4M.
Read more